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Clinician researchers have a number of roles, each of which carries specific obligations.
There are times when these obligations may be in competition (up to and including
conflict) with each other. Using a narrative case study that describes a group of colleagues
discussing their clinical department's participation in an industry-sponsored research
protocol, we illustrate a number of the obligations faced by clinician researchers, and
discuss how competing interests and obligations can lead to ethical problems. The case
study is followed by a discussion of the effect of university–industry relations on competing
interests and obligations in both clinical research and the role of the university, and a
suggested framework that could be used to determine when university involvement in
commercial research is ethically acceptable.
Keywords: clinical research ethics, competing interests, conflicts of interest, research
ethics, university–industry relations

DR. CÉZANNE'S STORY
Dr. Cézanne and his colleagues sit in silence as they prepare to discuss their participation in
the pharmaceutical company–sponsored clinical trial described in the pile of documents
lying on the table in front of them. Only their signatures are required for this multicenter
and multimillion-dollar, predesigned, and prepackaged proposal to proceed to their
university's research ethics board (REB). Dr. Cézanne knows he will be alone in his
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opposition to the proposal. His colleagues know they will patiently listen to Dr. Cézanne's
concerns, which he has brought to this table many times, and which they will disregard
again, even though they respect Dr. Cézanne as a serious scientist and as a caring physician.
It is indeed because they respect their well-intentioned but impractical friend, and because
théy all séé thémsélvés as “honorablé mén” that théy patiéntly comméncé thé discussion
that they already know will lead to the decision to participate in the trial. It's like a game
where the result has been predetermined.
One of Dr. Cézanne's colleagues plays his standard opening scientifically-sound card. “This
study is a well-designed, placebo-controlled, double-blind, randomized trial investigating
the efficacy and safety of a hormone replacement therapy. On page 7 of the drug company's
proposal, you can see that the number of patients that will be recruited nationally has the
statistical power to answer the scientific questions regarding whether the drug is effective
and safe. The methods of data analysis described on page 28 are appropriate. The proposal
is sciéntifically sound, and wé should participaté.”
Dr. Cézanne knows well the cards not-so-well concealed in his colleagues' well-intentioned,
science-driven, budget-responsible hands; powerful cards that compel the embrace of
pharmaceutical company--sponsored research. He counters with his re(peat)search card.
“Thé proposéd réséarch is not réséarch at all. It is ré(péat)séarch of a drug that has been
approved and prescribed for 10 years in Europe and 7 years in the United States. The only
justification for repeating the study on women in Canada would be if we believe
physiological differences exist between women in Canada and women in the United States
or Europe that might affect their tolerance of the drug or their risk of neoplasia. If
physiological differences do exist, they are more likely based on ethnic origin than on
country of residence. Although environment and diet are potential variables, these are
more likely to vary within each country than between sides of the 49th parallel of the
Atlantic Ocean.
A colleague promptly plays his Health-Canada-insists card. “You aré corréct, Dr. Cézanné,
the study is re(peat)search, but it is required by the Therapeutic Products Directorate of
Health Canada before patients can be prescribed this drug in Canada. The pharmaceutical
companiés aré forcéd by Héalth Canada to spénd théir millions.”
Dr. Cézanne quickly counters his lack-of-clinical-equipoise -card. “If thé pharmacéutical
companies must spend millions, why not spend the millions on a proper clinical trial? This
study is not research, for it lacks clinical equipoise (Freedman, 1987). The Canadian
philosopher, Benjamin Freedman, coined thé térm ‘clinical équipoisé’ to rémind us that if
the results of the study are apparent before the study commences, the study is not
research. We should change the protocol to compare the drug to the current gold standard
instead of placebo (Weijer, 1999; Weijer et al., 2000) and if the new product is more
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effective, and at least equally safe, we will learn something from the study rather than
possibly causing harm to Canadian women and gaining no new knowledge. The pain from
the endometrial biopsies required by the protocol and, for the women who receive placebo,
thé discomfort of théir symptoms, would bé an unjustifiablé harm.”
A colléagué uttérs, “You know wé can't changé thé protocol” as hé plays his participationis-in-the-best-interests-of-the-women-who-participaté card. “A woman, by énrolling in
research, can receive a drug that might better alleviate or even cure her problem years
before it will be available to her by prescription. There is also evidence that patients who
participate in clinical research may have better outcomes than those who do not
(Braunholz et al., 2001). And don't forget, the women in the study will get the drugs for free
and that is a significant bénéfit.”
Dr. Cézanne plays his non-nocéré card. “This proposal réquirés that all women undergo
endometrial biopsy to rule out endometrial neoplasia before they can be entered in the
study---all women---and these women cannot have a medical indication for endometrial
biopsy or they would not have met entry criteria. Venepuncture, although less painful, is
also required. Patients should not be asked by their physicians to endure painful
procedures with no benefit to science. We take an oath not to harm our patients
(Hippocratés, 1943) and this unnécéssary pain is harmful.”
A colleague counters with his patient-choicé card, “Our patiénts will not bé forcéd to
participate in this study. They will be offered the opportunity to freely choose to
participate, and, if they decide to participate, they will sign a consent form indicating that
they freely chose to participate. Our patients will be educated about the risks and potential
benefits by the study nurse before they consent. After considering what the study nurse has
said, a patiént can simply say, ‘I'd rathér not.’”
Dr. Cézanne counters with his lack-of-true-choicé card: “Raré is thé patiént who has thé
courage to refuse her physician's offer to enroll her in a clinical trial, as she perceives her
refusal as threatening to her prospects for good care in the future (Baylis, 1989; Kenny,
1994; Sherwin, 1994; Nisker and White, 2005). The woman fears her physician will think
less of her if she refuses to participate in a study that might forward the science that will
help other women, and she is sure the study her doctor is offering is important or her
doctor would not be asking. If she refuses, she feels she will offend her doctor. Further,
many patients feel the study drug is another treatment option (Kass et al., 1996), the option
théir doctors want thém to také.”
A colleague smiles and plays his more-choice-for-women -card. “Clinical trials, such as thé
one before us, are necessary to afford Canadian women the maximum number of choices
for the best drugs available. I cannot believe you of all people, Dr. Cézanne, would want to
limit women's choices.”
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Dr. Cézanne plays his more-marketing-than-méasuring card. “But thé proposéd study,
designed this way, is really just a marketing tool. The motivation for the pharmaceutical
company is to introduce their product to academic physicians like us, who will later
introducé théir product to privaté practicé physicians at ‘drug dinnérs,’ ‘drug lunchés,’ and
‘gétaway’ conféréncés. Wé unknowingly advértisé théir product in évéry léttér wé writé to
referring physicians regarding their patient qua research subject.”
A colleague plays his let-our-research-ethics-board-décidé card. “Our univérsity's REB is
well-known for screening research. You know how seriously its members take their jobs.
Why do you think you know moré than thé mémbérs of our REB?”
Dr. Cézanne counters with his lack-of-REB-knowledge-of-nuance card (Palca, 1996; Annas,
1994)” “Thé capacity for appropriaté REB réviéw résts firmly on thé shouldérs of thé
researchers whose signatures declare not only what is required on the REB application
form (carefully completed by pharmaceutical company or contract research staff), but all
information relevant to the REB deliberations. It is only fair to the REB members (and
especially to the women who will endure the pain) that it is clear that the proposal is
re(peat)search and that the gold standard drug is not part of the study, without
camouflaging these facts in creative wording, or submerging them in euphemisms extolling
the importance of the research to Canadian women. REB members rely on us researchers
to fully inform them of the specific ingredients and scientific worth of the study (Bok,
1995), and their study approval is inexorably linked to their confidence in our
understanding and integrity. We must, therefore, appreciate that our signatures today will
be interpreted by our REB as support of all aspects of the proposal; to condone, not just
non-condémn.”
A colleague plays his imperative-to-do-réséarch card. “If our céntér participatés in this
study, large amounts of the administrative money that will be accrued by the Department
will fund new research projects of yours, and many clinicians and trainees will have the
opportunity to develop clinical research skills, write papers, and ultimately apply for
funding to be independent investigators. Research is an imperative of our center, and
studiés liké this oné aré an important sourcé of réséarch funding.”
Dr. Cézanne plays his obligation-to-financial-transparéncy card: “Our céntér récéivés
hundréds of thousands of dollars for this ‘impérativé,’ and wé réséarchers personally
récéivé a thousand dollar ‘findér's féé’ for éach patiént who bécomés a participant. Our
patients have the right to know that we benefit financially. But by telling a patient we will
receive a thousand dollars if they consent to participate in the research, we may further
confiné hér choicé in favor of ‘voluntééring,’ as shé may béliévé that shé will hurt hér
physician's opinion of her if she refuses, and also hurt her physician's bank account and the
bank account of the institution that is providing hér caré.”
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Oné of Dr. Cézanné's colléagués éxclaims: “Why do you always focus on thé négativé
féaturés of évéry clinical trial that lands on this tablé?” whilé hé proudly plays his norestriction-to-publication card. “Théré aré so many positivé féatures of this study. For
example, nowhere in the 35 pages in front of you will you find any encumbrance on our
ability to publish the results of this study, no matter if the results declare the drug we are
testing to be clinically useless or even harmful.”
Dr. Cézanne nods that no clause inhibits publication of the findings, which is irrelevant for
this type of study. There will be no possibility for publication because there will be no new
findings. Though his colleagues have seen the recent media stories and medical journal
warnings (Gibson et al., 2002; Davidoff et al., 2001) in this regard, Dr. Cézanne is concerned
that his colleagues do not go deep enough, so he counters with his International-Council-ofMedical-Journal-Editors (ICMJE) card.
“Although the pharmaceutical company may not be prohibiting publication of the results,
the ICMJE will not allow its publication, as we will be breaking their rules. The
pharmaceutical company designed the study, will analyze and interpret the data, and have
a large part in writing the results-–and this means that many reputable journals will refuse
to publish it. We owe it to our students, our patients, our research participants, and indeed
ourselves to participate only in studies of adequate merit to be publishable in ICMJE
journals.”
Dr. Cézanne sees the shoulders slump around the table, like heavy rocks around a
smoldéring campfiré. No “Kumbaya” warms this communal contémplation. Rathér all aré
chilled by the silence. Finally, trying to move the card game to its inevitable conclusion, the
Department Chair plays his why-can't-you-compromisé card. Hé notés that, “Many othér
physicians, in many other Canadian centers have already agreed to participate in this study.
Seven university REBs have already approved this study. Are you suggesting they are not
moral physicians? Are the members of those REBs not moral? Are we, in our Department,
by choosing a road other than your high road, not moral men? I can't believe you believe
that. Can't you compromisé a littlé?”
Dr. Cézanne plays his final card, his ethics-is-not-compromisable card. He knows his
Départmént's Chair colléagué méans “compromisé” as a “balancing équation” or
“arbitration procéss to synthésizé individual viéwpoints to a group viéwpoint.” But Dr.
Cézanne hears “compromisé” as “adjust by concéssions,” “éxposé to risk, suspicion, or
disréputé,” “impéril.” Dr. Cézanné héars “compromisé” with incréasing fréquéncy,
increasingly branding his concerns as strident idealism inconsistent with modern research
realism. Dr. Cézanne is concerned his views separate him from his colleagues. Philosophers
have often been isolated for their positions: Socrates with hemlock, Spinoza with
excommunication, Voltaire with spending his life on the border of France and Switzerland
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near rapid retreat from whichever government he had most recently enraged. But Dr.
Cézanne is not a philosopher. He is a caring physician, and he doesn't want to be cut off
from their colleagues for caring.
Post-Cards
Dr. Cézanne still sits at that table. So do his colleagues and other physicians in his and other
institutions. Dr. Cézanne feels sorry for colleagues who cannot feel the fears that drive his
argumént. Hé undérstands “wé can bé éthical only in rélation to sométhing wé can féél,
understand, love, or othérwisé havé faith in” (Léopold, 1962). Hé fééls sorry that through
théir training in “milés of médical ink” and “consuming call schédulés,” his colléagués no
longer maintain the idealism of their youth (Nisker, 1997, 2003), or the calling to caring
(Kenny, 2002) that carried them to medical school. But if his colleagues' views have
become out-of-focus through wearing the multiple professional lenses of clinician and
researcher, should he not keep trying to re-refract their view?
Ethical decisions must be looked at within the context of their society, and particularly
relationships between individuals and institutions within their society. As governments
reduce research sponsorship, as hospitals face insolvency, and as universities fear for their
future, will fiscal pressure force fracture between fiscally-based and ethically-based
medical research? Dr. Cézanne believes that the REB process is but a fabric, the tightness of
weave largely dependent on the pens of the researchers. Dr. Cézanne hopes national and
international explorations will help sensitize researchers submitting proposals to their
REBs, to not only play by national and international rules, but to play within their spirit.
DISCUSSION
In the analysis of the story, we draw on the literatures on conflicts of interest, clinical
equipoise, and the commercialization of research in public institutions to explore the issues
raised by Cr. Cézanne's story.
Although one might argue that enlisting patients to participate in the study could be
considered a conflict of interest for the clinical researchers involved, and thus no further
discussion is required, this would be an oversimplification of the problem. The Institute of
Médiciné définés a conflict of intérést as “a sét of circumstancés that créatés a risk that
professional judgment or actions regarding a primary interest will be unduly influenced by
a sécondary intérést” (IOM, 2009). Bécausé thé réséarchérs participating in thé study
would récéivé a “findér's féé” for énrolling patiénts in thé study, a conflict of interest might
arise if they have patients whose best interests would not be served by participation in the
study. But there still seem to be problems with the study even if the researchers do not
accept a finder's fee, and these problems stem from the fact that factors other than
personal income are at stake. If we broaden the discussion from one of conflicts of interest
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to one of competing obligations, it becomes easier to see these factors and the problematic
role they play and, ultimately, to come to a position on the proposed research.
As clinicians, with primary obligations to their patients, Dr. Cézanne and his colleagues are
obligated to act in accordance with their patients' wishes and in their patients' best
interests (according to their patients' conception of their best interest). As scientists, they
are obligated to increase medical knowledge for the benefit of others in the future. As
employees (or as individuals with university appointments and hospital privileges), they
are required to participate in the training of students, to contribute to the generation of
knowledge, and, increasingly, to contribute to their institutions' financial well-being. We
suggest that a closer look at the challenge of managing these competing obligations
provides clues as to how to resolve the dispute between Dr. Cézanne and his colleagues.
Participation in a clinical trial may be beneficial to a patient, in that it may give her the
opportunity to try a new and promising treatment well before the therapy is available in
regular clinical care. At the same time, however, by enrolling in the trial, the patient also
runs the risk that she will not benefit and she also gives up the relative certainty of the
benefits of regular clinical care. At the very least, this creates an obligation for the clinicianresearcher to fully explain the potential benefits and harms of participation in the trial and
the alternative of receiving standard therapy.
It is important to note here, however, that society has placed restrictions on how much risk
a patient can be asked or allowed to assume (or, conversely, how much benefit she can
ethically be asked or allowed to forego) through participation in a clinical trial. Specifically,
a state of clinical equipoise must obtain in order for a trial to be ethically justifiable.
Benjamin Freedman (1987) defined clinical equipoise as a state of honest, professional
disagreement among the relevant medical community as to the best treatment. It must be
unclear to the experts whether the experimental intervention will be as or more safe and
effective than the currently accepted standard of care (or, where there is none or where the
standard of care has not been shown to be better than placebo, as or more effective than
placebo).
These rules do place limits on the physicians' obligations to act in accordance with the
wishes of their patients but they do so, in part, to correct for a power imbalance between
participants on the one hand and research sponsors on the other. Potential participants
have an interest in accessing a drug that they believe may benefit them. Research sponsors
have an interest in conducting research in the cheapest way possible with the greatest
chance of being able to claim superiority for their drug (e.g., placebo vs. active controls).
Without the rules, the research sponsors could force participants to accept inferior control
arms (i.e., placebo over standard of care) in order to gain even the possibility of access to
the drug.
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Given the rules, the most the physician could have an obligation to do (under obligations to
patients), is to offer them the opportunity to participate in a trial where clinical equipoise
exists and where standard therapy is the control. Neither of these conditions applies in this
scenario. Therefore, the physicians do not have any obligation under obligations to patients
to offer this trial to their patients.
Clinical equipoise is also an important principle in the analysis of the clinician-researchers'
obligations to advance medical knowledge for the benefit of others in the future. Resources
spent on this trial will not be available to spend on other trials. These resources include
clinic facilities time as well as scarce human resources. If clinical equipoise does not exist,
then surely better uses for these resources could be found. The study in Dr. Cézanne's
scenario will not enable the players to advance medical knowledge and so, at best, will not
contribute to them meeting their obligations; it will, at worst, interfere with their ability to
meet their obligations (by distracting them from studies that could actually advance
medical knowledge).
In sum, so far, we have seen that for Dr. Cézanne and his colleagues, proceeding with this
clinical trial will not help them to attend to their obligations as clinicians (who must act
according to their patients' wishes and in their patients' best interests as seen by the
patients) and as scientists (who must conduct research that is both ethical and of scientific
value) within the limits society has placed on thosé obligations. A “ré(péat)séarch” study,
such as the one described here, being of questionable scientific value and requiring patients
to accept worse care than they would receive in regular clinical practice in order to access
the experimental intervention, fails with respect to both of these sets of obligations.
However, Dr. Cézanne and his colleagues have another set of obligations that may seem to
push them in the direction of approving the study. These are their obligations to the
institution where they work. As employees (or individuals with appointments and
privileges), they are required to participate in the training of students, contribute to the
generation of knowledge, and, increasingly, to contribute to their institutions' financial
well-being.
If Dr. Cézanne and his colleagues participate in the study, their institution will receive
funding that can be used to support trainees and to cover infrastructure costs. In fact, it is
increasingly common that research institutions receive a significant portion of their
operating funds from industry-sponsored research. This research may be contracted by the
industry partner, or may be a joint venture undertaken with the hope of commercializable
results. The increase in such research is due both to the hope of profitable research and to
the fact that government funding of universities and other research institutes (both directly
and through granting programs) has not kept pace with the increasing costs of running the
institution or with the costs of research itself. These changes in the way in which
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universities are funded have resulted in changes to obligations that researchers have
toward them. Increasingly, researchers' time is spent trying to attract funding for their own
research, a portion of which is kept by the university to cover its costs. This study will, of
course, help with all of this and so contribute to Dr. Cézanne and his colleagues meeting
their obligations with respect to the financial well-being of their institution.
However, the study will undermine their ability to meet their other obligations which arise
as a result of their relationship with the institution: teaching and creating new knowledge.
At first blush, it might appear otherwise. Students who work on the study will certainly
learn about research and some knowledge will be produced through the research. But will
the lessons the students learn be good ones, and will the knowledge gained be new and
useful for science or medicine?
We would argue that the duty of the university is actually broader than the mere teaching
and the mere acquisition of knowledge. We would argue that universities have a duty to
educate students and to develop knowledge in ways that can be used to benefit society.
Universities should not simply become a source of researchers for hire for corporations.
Universities should not simply become factories for knowledge that serves the marketing
purposes of industry. Requiring that studies undertaken by academic institutions have
social or scientific value prevents these consequences from being realized.
The study debated by Dr. Cézanne and his colleagues fails the test of social or scientific
value both in terms of teaching and knowledge generation: the students will learn to devote
their time and intellectual energy to the highest bidder rather than the health of their
patients and future patients; and a number of other effective treatments are already
available, and the study's purpose is not to answer a scientific question (it is already known
that the drug is effective). Therefore, while the obligation to generate resources can be met
through this study, the clinician-researchers' obligations to their institution in respect of
teaching and knowledge generation cannot.
In sum, agreeing to run this clinical trial will not serve the clinician-researchers' obligations
as clinicians or as researchers. Nor will it serve two of their three kinds of obligations as
employees (or as individuals with appointments and privileges)-–it will enable them to
generate funds but not to meet the teaching and knowledge generation mandates of a
university. Thus, the competition is relatively easy to resolve-–money against all else-–and
they should not agree to run the study.
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Figure 1: Paul Cézanne: The Card Players (Les joueurs de cartes) 1890–1892.
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